|
Market Cap | 245.10M | EPS (ttm) | 0.25 |
P/E | 35.15 | EPS this Y | 125.00% |
Forward P/E | 9.37 | EPS next Y | 59.83% |
PEG | - | EPS past 5Y | -20.02% |
P/S | 0.42 | EPS next 5Y | -1.00% |
P/B | 0.68 | EPS Q/Q | -16.36% |
Dividend | 1.37% | Sales Q/Q | 8.21% |
Insider Own | 6.72% | Inst Own | 81.72% |
Insider Trans | 1.44% | Inst Trans | -4.28% |
Short Float | 3.62% | Earnings | May 09/a |
Analyst Recom | 1.00 | Target Price | 18.00 |
Avg Volume | 203.83K | 52W Range | 8.41 - 18.38 |
|
|
|
American Vanguard Corp. is a holding company which engages in the development and marketing of specialty and agricultural products for crop protection and management, turf and ornamentals management, public and animal health. It also acquires and licenses both new and well-established product lines that serve numerous market niches. The company was founded by Herbert A. Kraft and Glenn A. Wintemute in January 1969 and is headquartered in Newport Beach, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Macicek Steven D | Director | May 15 '24 | Buy | 9.01 | 8,500 | 76,624 | 10,044 | May 17 06:26 AM | Trogele Ulrich | See Remarks | Dec 14 '23 | Buy | 10.72 | 5,000 | 53,625 | 191,676 | Dec 14 08:30 PM | Trogele Ulrich | See Remarks | Dec 11 '23 | Buy | 10.05 | 2,488 | 25,004 | 186,676 | Dec 12 02:13 PM | Trogele Ulrich | See Remarks | Dec 07 '23 | Buy | 9.97 | 5,015 | 50,000 | 184,188 | Dec 12 02:09 PM | ROSENBLOOM KEITH M | Director | Nov 21 '23 | Buy | 9.05 | 5,700 | 51,579 | 974,155 | Nov 22 04:18 PM |
|
|
|
|
Market Cap | 380.88M | EPS (ttm) | -0.50 |
P/E | - | EPS this Y | 13.33% |
Forward P/E | - | EPS next Y | -23.08% |
PEG | - | EPS past 5Y | -9.03% |
P/S | - | EPS next 5Y | - |
P/B | 2.78 | EPS Q/Q | 23.60% |
Dividend | - | Sales Q/Q | - |
Insider Own | 3.16% | Inst Own | 37.85% |
Insider Trans | -2.49% | Inst Trans | -1.98% |
Short Float | 25.97% | Earnings | May 09/b |
Analyst Recom | 1.00 | Target Price | 27.50 |
Avg Volume | 1.29M | 52W Range | 3.25 - 10.45 |
|
|
|
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Thomas Steffen | Director | May 15 '24 | Buy | 4.52 | 5,000 | 22,600 | 5,000 | May 17 06:01 AM | MISSLING CHRISTOPHER U | President and CEO | Mar 28 '24 | Option Exercise | 1.32 | 73,380 | 96,862 | 1,323,590 | Apr 01 06:00 PM | MISSLING CHRISTOPHER U | President and CEO | Mar 28 '24 | Sale | 5.11 | 73,380 | 374,972 | 1,250,210 | Apr 01 06:00 PM | MISSLING CHRISTOPHER U | President and CEO | Jun 29 '23 | Option Exercise | 1.60 | 232,000 | 371,200 | 1,250,210 | Jun 30 08:00 PM | MISSLING CHRISTOPHER U | President and CEO | Jun 28 '23 | Option Exercise | 1.60 | 268,000 | 428,800 | 1,286,210 | Jun 30 08:00 PM |
|
|
|
|
Market Cap | 326.42M | EPS (ttm) | -1.52 |
P/E | - | EPS this Y | 110.81% |
Forward P/E | 8.99 | EPS next Y | 68.42% |
PEG | - | EPS past 5Y | - |
P/S | 1.34 | EPS next 5Y | - |
P/B | 0.82 | EPS Q/Q | 120.38% |
Dividend | - | Sales Q/Q | -12.46% |
Insider Own | 53.38% | Inst Own | 9.13% |
Insider Trans | 0.27% | Inst Trans | 0.10% |
Short Float | 2.26% | Earnings | May 10/b |
Analyst Recom | 1.00 | Target Price | 9.00 |
Avg Volume | 139.93K | 52W Range | 4.07 - 9.22 |
|
|
|
AlTi Global, Inc. is a financial services company, which engages in the provision of investment, advisory, and administrative services. The company was founded on December 18, 2020 and is headquartered in New York, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Keaney Timothy F | President, Asset Management | May 16 '24 | Buy | 4.60 | 16,417 | 75,518 | 97,321 | May 16 09:34 PM | Keaney Timothy F | President, Asset Management | May 15 '24 | Buy | 4.52 | 50,195 | 226,881 | 80,904 | May 16 09:34 PM | Keaney Timothy F | President, Asset Management | May 14 '24 | Buy | 4.62 | 17,598 | 81,303 | 30,709 | May 16 09:34 PM | Moran Kevin P. | See Remarks | May 14 '24 | Sale | 4.70 | 591 | 2,778 | 175,184 | May 16 05:03 PM | ilWaddi Cayman Holdings | 10% Owner | Apr 03 '24 | Buy | 4.99 | 20,000 | 99,800 | 17,933,265 | Apr 04 04:15 PM |
|
|
| |
|
Market Cap | 49.49M | EPS (ttm) | -0.25 |
P/E | - | EPS this Y | 2.50% |
Forward P/E | - | EPS next Y | 48.72% |
PEG | - | EPS past 5Y | 26.38% |
P/S | 1649.79 | EPS next 5Y | 35.00% |
P/B | 2.16 | EPS Q/Q | 7.76% |
Dividend | - | Sales Q/Q | - |
Insider Own | 4.69% | Inst Own | 19.34% |
Insider Trans | 11.97% | Inst Trans | 1.12% |
Short Float | 3.42% | Earnings | May 15/a |
Analyst Recom | 1.00 | Target Price | 3.00 |
Avg Volume | 489.87K | 52W Range | 0.37 - 1.76 |
|
|
|
Aqua Metals, Inc. engages in reinventing metal recycling technologies. Its patented technology, AquaRefining, replaces polluting furnaces and hazardous chemicals with electricity-powered electroplating to recover valuable metals and materials from spent batteries with higher purity, lower emissions, and minimal waste. The company was founded by Stephen R. Clarke, Thomas Murphy, and Selwyn Mould on June 20, 2014 and is headquartered in Reno, NV. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Cotton Stephen | Chief Executive Officer | May 14 '24 | Buy | 0.39 | 250,000 | 97,500 | 6,352,233 | May 16 08:11 PM | YI SUNG | Director | May 14 '24 | Buy | 0.39 | 75,000 | 29,250 | 105,500 | May 16 09:33 PM | DIVITO VINCENT L | Director | May 14 '24 | Buy | 0.39 | 62,500 | 24,375 | 421,698 | May 16 08:18 PM | Zhang Peifang | Director | May 14 '24 | Buy | 0.39 | 62,500 | 24,375 | 313,550 | May 16 08:20 PM | Merrill Judd | Chief Financial Officer | May 14 '24 | Buy | 0.39 | 37,500 | 14,625 | 2,076,416 | May 16 08:12 PM |
|
|
|
|
Market Cap | 51.55M | EPS (ttm) | -0.49 |
P/E | - | EPS this Y | 37.78% |
Forward P/E | - | EPS next Y | 92.86% |
PEG | - | EPS past 5Y | 30.03% |
P/S | 1.50 | EPS next 5Y | 10.00% |
P/B | 0.81 | EPS Q/Q | -11.23% |
Dividend | - | Sales Q/Q | -20.43% |
Insider Own | 17.16% | Inst Own | 15.55% |
Insider Trans | 81.43% | Inst Trans | -15.62% |
Short Float | 0.87% | Earnings | May 15/a |
Analyst Recom | 1.00 | Target Price | 8.75 |
Avg Volume | 87.65K | 52W Range | 1.83 - 3.60 |
|
|
|
IZEA Worldwide, Inc. engages in the creation and operation of online marketplaces that connect marketers with content creators under IZEAx platform. It automates influencer marketing and custom content development, which allows brands and agencies to scale their marketing programs. The company was founded by Edward Hans Murphy in February 2006 and is headquartered in Orlando, FL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
GP Investments, Ltd. | 10% Owner | May 16 '24 | Buy | 2.77 | 178,330 | 493,974 | 3,002,036 | May 16 08:45 PM | GP Investments, Ltd. | 10% Owner | May 14 '24 | Buy | 3.20 | 928,114 | 2,969,965 | 2,823,706 | May 16 08:45 PM | GP Investments, Ltd. | 10% Owner | May 10 '24 | Buy | 3.14 | 102 | 320 | 1,895,592 | May 13 06:33 PM | GP Investments, Ltd. | 10% Owner | May 09 '24 | Buy | 3.06 | 38,021 | 116,344 | 1,895,490 | May 13 06:33 PM | GP Investments, Ltd. | 10% Owner | May 03 '24 | Buy | 3.00 | 1,427 | 4,281 | 1,857,469 | May 03 06:21 PM |
|
|
| |
|
Market Cap | 242.26M | EPS (ttm) | -0.57 |
P/E | - | EPS this Y | -68.86% |
Forward P/E | - | EPS next Y | 33.80% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | 0.83% |
Dividend | - | Sales Q/Q | - |
Insider Own | 29.67% | Inst Own | 51.29% |
Insider Trans | -29.54% | Inst Trans | 2.15% |
Short Float | 22.90% | Earnings | May 10/b |
Analyst Recom | 1.80 | Target Price | 4.40 |
Avg Volume | 778.31K | 52W Range | 1.12 - 13.51 |
|
|
|
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Weber Darin J. | SVP of Regulatory Development | Apr 22 '24 | Sale | 2.51 | 16,438 | 41,315 | 155,194 | Apr 23 04:05 PM | Weber Darin J. | SVP of Regulatory Development | Apr 18 '24 | Sale | 2.54 | 800 | 2,028 | 171,632 | Apr 23 04:05 PM | Weber Darin J. | SVP of Regulatory Development | Apr 16 '24 | Sale | 2.50 | 17,238 | 43,095 | 172,432 | Apr 17 06:57 PM | Weber Darin J. | SVP of Regulatory Development | Apr 12 '24 | Sale | 1.73 | 84,103 | 145,498 | 189,670 | Apr 16 04:54 PM | Weber Darin J. | SVP of Regulatory Development | Apr 01 '24 | Sale | 1.69 | 300 | 507 | 273,773 | Apr 16 04:54 PM |
|
|
|
|
Market Cap | 48.75M | EPS (ttm) | -0.09 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -55.14% |
P/S | 0.66 | EPS next 5Y | 22.50% |
P/B | 2.27 | EPS Q/Q | 151.26% |
Dividend | - | Sales Q/Q | -2.62% |
Insider Own | 18.40% | Inst Own | 40.89% |
Insider Trans | -0.88% | Inst Trans | -8.38% |
Short Float | 0.06% | Earnings | May 09/b |
Analyst Recom | 1.00 | Target Price | 20.00 |
Avg Volume | 26.58K | 52W Range | 8.79 - 16.85 |
|
|
|
BK Technologies Corp. is a holding company, which engages in the provision of two-way radio communications equipment. It offers product to the fire, EMS, police, federal, and municipalities agencies. The company was founded on October 24, 1997 and is headquartered in West Melbourne, FL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Horowitz Joshua | Director | May 16 '24 | Buy | 13.77 | 8,169 | 112,462 | 80,809 | May 16 08:07 PM | Horowitz Joshua | Director | May 15 '24 | Buy | 13.45 | 5,572 | 74,953 | 72,640 | May 16 08:07 PM | Horowitz Joshua | Director | May 14 '24 | Buy | 13.23 | 2,893 | 38,280 | 67,068 | May 16 08:07 PM | Fundamental Global GP, LLC | 10% Owner | Jan 30 '24 | Sale | 12.29 | 7,053 | 86,681 | 248,975 | Jan 31 07:22 PM | Fundamental Global GP, LLC | 10% Owner | Jan 29 '24 | Sale | 12.49 | 13,906 | 173,686 | 256,028 | Jan 31 07:22 PM |
|
|
| |
|
Market Cap | 32.83M | EPS (ttm) | -1.09 |
P/E | - | EPS this Y | 10.61% |
Forward P/E | - | EPS next Y | 23.55% |
PEG | - | EPS past 5Y | 2.69% |
P/S | 0.59 | EPS next 5Y | - |
P/B | 1.64 | EPS Q/Q | 57.32% |
Dividend | - | Sales Q/Q | 28.36% |
Insider Own | 25.01% | Inst Own | 35.78% |
Insider Trans | 0.48% | Inst Trans | -0.83% |
Short Float | 0.03% | Earnings | May 13/b |
Analyst Recom | 1.33 | Target Price | 5.50 |
Avg Volume | 45.33K | 52W Range | 1.30 - 3.92 |
|
|
|
Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
ABALLI JOHN | President and CEO | May 16 '24 | Buy | 1.92 | 40,401 | 77,570 | 40,401 | May 16 08:02 PM | Adawi Kamal | CFO and Corporate Secretary | Mar 04 '24 | Sale | 1.91 | 12,784 | 24,407 | 243,749 | Mar 06 04:05 PM | Adawi Kamal | CFO and Corporate Secretary | Feb 06 '24 | Sale | 1.95 | 6,738 | 13,133 | 181,533 | Feb 08 04:05 PM | ABALLI JOHN | President and CEO | Oct 17 '23 | Sale | 1.75 | 33,819 | 59,018 | 415,984 | Oct 18 04:05 PM | TULLIS JAMES L L | 10% Owner | Jun 15 '23 | Buy | 3.11 | 167 | 519 | 1,515,839 | Jun 20 05:04 PM |
|
|
|
|
Market Cap | 124.46M | EPS (ttm) | -1.07 |
P/E | - | EPS this Y | -508.33% |
Forward P/E | - | EPS next Y | 49.68% |
PEG | - | EPS past 5Y | - |
P/S | 0.31 | EPS next 5Y | - |
P/B | 0.38 | EPS Q/Q | -7986.04% |
Dividend | - | Sales Q/Q | 24.10% |
Insider Own | 30.26% | Inst Own | 71.45% |
Insider Trans | -0.16% | Inst Trans | 32.39% |
Short Float | 17.96% | Earnings | May 09/b |
Analyst Recom | 2.71 | Target Price | 4.08 |
Avg Volume | 3.54M | 52W Range | 1.70 - 28.13 |
|
|
|
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Quimi Daphne | Director | May 15 '24 | Buy | 1.89 | 2,250 | 4,252 | 5,000 | May 16 07:37 PM | Mazzariello Gina | Chief Legal Officer | May 15 '24 | Sale | 1.88 | 10,455 | 19,654 | 151,477 | May 16 07:36 PM | Quimi Daphne | Director | May 14 '24 | Buy | 1.89 | 2,750 | 5,184 | 2,750 | May 16 07:37 PM | Klee Justin B. | Co-Chief Executive Officer | Mar 05 '24 | Sale | 18.73 | 4,135 | 77,440 | 2,959,308 | Mar 07 04:05 PM | Cohen Joshua B | Co-Chief Executive Officer | Mar 05 '24 | Sale | 18.73 | 4,135 | 77,440 | 3,023,002 | Mar 07 04:05 PM |
|
|
|
|
Market Cap | 343.03M | EPS (ttm) | -0.66 |
P/E | - | EPS this Y | 259.20% |
Forward P/E | 11.13 | EPS next Y | 38.33% |
PEG | - | EPS past 5Y | - |
P/S | 1.31 | EPS next 5Y | 16.00% |
P/B | 2.69 | EPS Q/Q | 101.98% |
Dividend | - | Sales Q/Q | 8.56% |
Insider Own | 32.61% | Inst Own | 62.82% |
Insider Trans | 0.24% | Inst Trans | -9.68% |
Short Float | 3.21% | Earnings | May 07/a |
Analyst Recom | 1.33 | Target Price | 22.20 |
Avg Volume | 402.81K | 52W Range | 7.97 - 18.45 |
|
|
|
Turtle Beach Corp. engages in the development, commercialization, and marketing of audio peripherals. The firm provides gaming accessory. The company was founded by Elwood G. Norris and James A. Barnes in 1975 and is headquartered in White Plains, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Jimenez Terry | Director | May 14 '24 | Buy | 16.37 | 2,025 | 33,149 | 40,909 | May 16 07:23 PM | Jimenez Terry | Director | May 09 '24 | Buy | 16.25 | 2,025 | 32,906 | 38,884 | May 13 05:27 PM | Scherping Katherine Lee | Director | Jun 05 '23 | Buy | 10.75 | 500 | 5,375 | 15,857 | Jun 06 04:05 PM | Scherping Katherine Lee | Director | Jun 02 '23 | Buy | 11.00 | 500 | 5,500 | 15,357 | Jun 06 04:05 PM | Jimenez Terry | Director | May 19 '23 | Buy | 11.59 | 2,500 | 28,975 | 26,551 | May 22 06:11 PM |
|
|
|